GlassScriptPhysician profile
Michael W Morris
NPI 1750358792
$9,578.21
in general payments reported to CMS, 2019-2025
45 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $730 · 2021: $1,394 · 2022: $1,442 · 2023: $1,942 · 2024: $1,261 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,394 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,394.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,194.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,035.07 | 2020-2025 | |
| Pfizer INC. | $1,007.96 | 2019-2025 | |
| Amgen INC. | $921.28 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $864.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $606.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $565.75 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $465.83 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $422.56 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.42 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $275.49 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $219.76 | 2020-2024 | Ajovy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $175.15 | 2019-2024 | Rexulti |
| Amarin Pharma, INC. | $117.69 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $111.51 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.